Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9UM00
UPID:
TMCO1_HUMAN
Alternative names:
GEL complex subunit TMCO1; Transmembrane and coiled-coil domain-containing protein 1; Transmembrane and coiled-coil domains protein 4; Xenogeneic cross-immune protein PCIA3
Alternative UPACC:
Q9UM00; B2REA0; J9JIE6; O75545; Q9BZS3; Q9BZU8
Background:
The Calcium load-activated calcium channel, known as TMCO1, plays a pivotal role in maintaining calcium homeostasis by preventing calcium stores from overfilling. It forms a homotetramer in response to endoplasmic reticulum (ER) overloading, regulating calcium content within the ER. TMCO1 is also a component of the multi-pass translocon (MPT) complex, crucial for inserting multi-pass membrane proteins into lipid bilayers.
Therapeutic significance:
TMCO1's involvement in Craniofacial dysmorphism, skeletal anomalies and impaired intellectual development syndrome 1, and its association with Glaucoma, primary open angle, underscores its potential as a target for therapeutic intervention. Understanding TMCO1's role could lead to novel treatments for these conditions.